Form 4 for DXCM Dexcom
Accepted 2021-12-17 00:00:00 ET · period of report 2021-12-15 · accession 0001093557-21-000288 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-17 | 2021-12-15 | DXCM | Patterson Chad | EVP, Gbl Marketing | A - Grant | $0.00 | +2,925 | 12.5K | +30% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-15 | A | A | 2,925 | $0.00 | 12,528 | D | — | — | (F1) Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock. (F2) Included in this number are 12,528 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,394 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 575 of which were granted on March 8, 2019 and shall vest through March 8, 2022. |